Drug Trial Radar · NCT06323824
Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Jun 4, 2024
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Yale UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH); National Institute on Drug Abuse (NIDA); The Emmes Company, LLC; University of California, San Francisco; Boston Medical Center (BMC); Hennepin Healthcare Research Institute; Alameda Health System; Marshall Health; Kaiser Permanente
- First posted
- Mar 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to compare the effectiveness of office-based methadone with pharmacy administration and/or dispensing to office-based buprenorphine for the treatment of opioid use disorder. This study will also examine factors influencing the implementation of office-based methadone.
Conditions
- Opioid Use Disorder
Interventions
MethadoneDrug
Drug: Methadone Possible formulations: 10 and 50 mg tablets
Buprenorphine (BUP)Drug
Drug: Buprenorphine (BUP) Possible formulations: A. Buprenorphine, 225 mcg to 24 mg, 225 mcg to 32 mg per day, B. Buprenorphine (Extended release), 300 mg q 28 days (Sublocade), 100 mg q 28 days (Sublocade), 8 mg q 7 days (Brixadi), 16 mg q 7 days (Brixadi), 24 mg q 7 days (Brixadi), 32 mg q 7 days (Brixadi), 64 mg q 28 days (Brixadi), 96 mg q 28 days (Brixadi), 128 mg q 28 days (Brixadi),
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of days of continuous treatment with site clinician-prescribed methadone or buprenorphine, as randomized, during the 168 days post-randomization among RCT participants.Time frame: up to Day 168
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Highland Hospital Bridge Clinic at Alameda Health System
Oakland, California · Recruiting
Outpatient Buprenorphine Induction Clinic, University of California, San Francisco
San Francisco, California · Recruiting
Rapid Start Clinic, Kaiser Permanente Colorado
Denver, Colorado · Recruiting
Officed Based Addiction Treatment Program, Boston Medical Center
Boston, Massachusetts · Recruiting
Hennepin Healthcare Addiction Medicine
Minneapolis, Minnesota · Recruiting
Marshall University Division of Addiction Sciences P.R.O.A.C.T
Huntington, West Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.